STABILITY INDICATING HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD FOR DETERMINATION OF ATAZANAVIR AND RITONAVIR IN COMBINED TABLET DOSAGE FORMS

Deshpande Padmanabh B, 1,2, Butle Santosh R. 2
1AISSMS College of Pharmacy, Kennedy Road, Near RTO, Pune, Maharashtra, India
2School of Pharmacy, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra, India

*Corresponding Author Email: padmanabh77@yahoo.co.in
DOI: 10.7897/2277-4572.035197

Received on: 25/08/14 Revised on: 25/09/14 Accepted on: 07/10/14

ABSTRACT
A new simple, accurate, precise and selective stability-indicating high performance thin layer chromatographic (HPTLC) method has been developed and validated for simultaneous estimation of Atazanavir and Ritonavir in combined tablet dosage form. The mobile phase selected was Toluene: Ethyl acetate: Methanol (6: 4.5: 0.6, v/v/v) with UV detection at 240 nm. The retention factor for Atazanavir and Ritonavir were found to be 0.25 ± 0.004 and 0.41 ± 0.004. The method was validated with respect to linearity, accuracy, precision and robustness. The drugs were subjected to stress condition of hydrolysis (acid, base), oxidation, photolysis and thermal degradation. Results found to be linear in the concentration range of 1000-8000 ng band for Atazanavir and 500-4000 ng band for Ritonavir respectively. The method has been successfully applied for the analysis of drugs in pharmaceutical formulation. The % assay (Mean ± S.D.) was found to be 100.40 ± 0.964 for Ritonavir and 99.59 ± 1.103 for Atazanavir.

Keywords; Ritonavir, Atazanavir, Forced degradation, Tablet dosage form

INTRODUCTION
Atazanavir (ATV), chemically, (3S,8S,9S,12S)-3,12-bis(1,1-dimethylallyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[(4-(2-pyridinyl)phenyl) methyl]-2,5,6,10,13-pentaaza tetra decanoic acid dimethyl ester which is inhibitor of HIV-1 protease. Ritonavir (RTV), 2, 4, 7, 12-Tetraazatridecane-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylpyrrolyl)-1-[2-(1-methylpyrrolyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-5-thiazolylmethyl ester [5S-(5R*,8R*,10R*,11R*)] is a potent cytochrome P-450 (CYP3A) inhibitor and usually used as pharmacokinetic booster for other protease inhibitor including Atazanavir, thereby providing increased plasma level of Atazanavir. Literature survey reveals High Performance Liquid Chromatographic (HPLC)1-9, LC-MS10 and Ultra Performance Liquid Chromatography (UPLC)11 methods for determination of ATV as single and in combination with other drugs in human plasma. Also Spectrophotometric method for degradation studies of ATV in dosage form has been also reported12. Analytical methods reported for RTV includes HPLC13-15 LC-MS16, Densitometry17-19 and spectrophotometry20 either as single or in combination with other drugs. No reports were found for stability-indicating HPTLC method for simultaneous determination of ATV and RTV in tablet dosage form. This paper describes simple, precise, accurate and sensitive HPTLC method development and validation as well as stability study (hydrolysis, oxidation, photo-degradation and thermal degradation) as per International Conference on Harmonization Guidelines21,22.

MATERIALS AND METHODS
Reagents and chemicals
Analytically pure samples of RTV and ATV were kindly supplied by Emcure Pharma Pvt. Ltd. (Pune, India) and Cipla Pvt. Ltd. (Kurkumbh, India) respectively. The pharmaceutical dosage form used in this study was Sinthivan tablets (Cipla Pvt. Ltd., Patalganga, India) labeled to contain 300 mg of ATV and 100 mg of RTV were procured from the local market. Toluene and Methanol (AR grade) were obtained from Thomas Baker Pvt Ltd (Mumbai, India). Ethyl acetate was obtained from Loba Chemie Pvt Ltd. (Mumbai, India).

Instrumentation and Chromatographic conditions
The samples were spotted in the form of bands of width of 6 mm with space between bands of 10 mm, with a 100 µL sample syringe (Hamilton, Bonaduz, Switzerland) on precoated silica gel aluminum plate 60 F254 (10 × 10) with 250 µm thickness (E. MERCK, Darmstadt, Germany) using a CAMAG Linomat 5 sample applicator (Switzerland). The slit dimensions 5 mm × 0.45 mm and scanning speed of 20 mm/sec was employed. The linear ascending development was carried out in 10 cm × 10 cm twin trough glass chamber (CAMAG, Muttenz, Switzerland) using Toluene: Ethyl acetate: Methanol (6: 4.5: 0.6 v/v/v) as mobile phase. The optimized chamber saturation time for mobile phase was 15 minutes. The length of chromatogram run was 9 cm and development time was approximately 15 minutes. TLC plates were dried in a current of air with the help of a hair drier. Densitometric scanning was performed on CAMAG thin layer chromatography scanner at 240 nm for all developments operated by WINCATS software version 1.4.2. The source of radiation utilized was deuterium lamp emitting a continuous UV spectrum between 200 to 400 nm.

Preparation of Standard Stock Solutions
Standard stock solution of RTV and ATV were prepared by dissolving 10 mg of drug in 10 mL of methanol to get concentration of 1 mg mL-1 from which 5 mL was further diluted to 10 mL to get stock solution of 500 ng µL-1 of RTV and ATV respectively.

Selection of Detection Wavelength
After chromatographic development bands were scanned over the range of 200-400 nm and the spectra were overlain. It was observed that both drugs showed considerable absorbance at 240 nm. So, 240 nm was selected as the wavelength for detection.
Analysis of Tablet Formulation

Twenty tablets were weighed accurately and finely powdered. A quantity of powder equivalent to 5 mg of RTV (15 mg ATV) was weighed and dissolved in 10 mL of methanol. The solution was filtered using Whatman paper No. 41 and two μL volume of this solution was applied on TLC plate to obtain final concentration of 1000 ng band⁻¹ for RTV and 3000 ng band⁻¹ for ATV. After chromatographic development peak areas of the bands were measured at 240 nm and the amount of each drug present in sample was estimated from the respective calibration curves. Procedure was repeated six times for the analysis of homogenous sample.

Stress degradation studies of bulk drug

Forced degradation studies were carried out to provide evidence on how stability of drug varies under the influence of variety of environmental conditions like hydrolysis, oxidation, temperature, etc. and to establish specific storage conditions, shelf-life and retest period.

Acid treatment

1 mL working standard solution of ATV (500 ng μL⁻¹) was mixed with 1 mL of 0.1 N HCl (methanolic) and 8 mL of methanol. The mixture was refluxed for half an hour. 4 μL of the resulting solution was applied to HPTLC. RTV was treated in similar manner to ATV.

Alkali treatment

1 mL working standard solution of ATV (500 ng μL⁻¹) was mixed with 1 mL of 0.1 N NaOH and 8 mL of methanol. The mixture was refluxed for two hour. 4 μL of the resulting solution was applied to HPTLC. RTV was treated in similar manner to ATV.

Oxidative degradation

1 mL working standard solution of ATV (500 ng μL⁻¹) was mixed with 1 mL of 30 % solution of H₂O₂ and 8 mL of methanol. The mixture was refluxed for three hour. 4 μL of the resulting solution was applied to HPTLC. RTV was treated in similar manner to ATV.

Neutral Hydrolysis

1 mL working standard solution of ATV was mixed with 9 mL water. The solution was refluxed for one h in dark place. 4 μL of the resulting solution was applied to HPTLC. RTV was treated in similar manner to ATV.

Photo-degradation

Photolytic studies were carried out by exposure of drug to UV light up to 200 watt hours square meter⁻¹ and subsequently to fluorescence light illumination not less than 1.2 million lux hours. Sample was weighed, dissolved in methanol to get concentration of 500 μg mL⁻¹. 4 μL of the resulting solutions was applied to HPTLC.

Degradation under dry heat

Dry heat study was performed by keeping ATV in oven at 60°C for 7 days. A sample was withdrawn at appropriate times, weighed and dissolved in methanol to get solution of 500 ng μL⁻¹. 4 μL of the resulting solutions was applied to HPTLC. RTV was treated in similar manner to ATV.

RESULTS AND DISCUSSION

Optimization of chromatographic conditions

The primary target in developing this stability indicating HPLC method is to achieve the resolution between ATV, RTV and its degradation products. The separation was achieved by linear ascending development in 10 cm × 10 cm twin trough glass chamber using Toluene: Ethyl acetate: Methanol (6: 4.5: 0.6 v/v/v) as mobile phase. The optimum wavelength for detection and quantitation used was 240 nm. The retention factors for RTV and ATV were found to be 0.25 ± 0.004 and 0.41 ± 0.004 respectively. Representative densitogram of mixed standard solution of RTV and ATV is shown in Figure 1.

Result of forced degradation studies

Forced degradation study showed the method is highly specific and no degradation products were eluted at retention time of drugs.

Acid treatment

14 % of ATV and 33 % of RTV degraded in acid condition when refluxed for half an hour. However no additional degradation peaks were seen in the densitogram for ATV. The representative densitogram after acid treatment is shown in Figure 2.

Alkali treatment

36 % of degradation of RTV was observed in alkaline condition while 13 % degradation of ATV was observed with no additional degradation peak. The representative densitogram after alkali treatment is shown in Figure 3.

Oxidative degradation

22 % degradation was observed for ATV when treated with 30 % H₂O₂ while RTV exhibited 8 % degradation. The representative densitogram after oxidative degradation is shown in Figure 4.

Neutral Hydrolysis

ATV was found to be stable in neutral condition when refluxed for one hour while 16 % of degradation was observed for RTV with degradation peaks at Rf 0.16, 0.30. The representative densitogram after neutral degradation is shown in Figure 5.

Photo Degradation Studies

ATV and RTV were found to be stable in ultraviolet light (200 Watt hours/Secuare meter) as well as flurosence light (1.2 million lux hours).

Dry Degradation Studies

The solid state studies showed that the drug substances ATV and RTV were stable to the effect of temperature when the powdered drug substance was exposed to dry heat at 60°C for 7 days. Peak purity results greater than 990 indicate that ATV and RTV peaks are homogeneous in all stress conditions tested. The unaffected assay of ATV and RTV in the tablet confirms the stability indicating power of the method. The forced degradation studies data are summarized in Table 1.
**Method Validation**

The method was validated for linearity, accuracy, intra-day and inter-day precision and robustness, in accordance with ICH guidelines.\(^2\)

**Preparation of Calibration Curve**

The standard stock solutions of RTV and ATV (500 ng µL each) were applied by over spotting on TLC plate in range of 1, 2, 3, 4, 5, 6, 7, 8 µL and 2, 4, 6, 8, 10, 12, 14, 16 µL respectively. Straight-line calibration graphs were obtained for RTV and ATV in the concentration range 500-4000 ng band\(^{-1}\) for RTV and 1000-8000 ng band\(^{-1}\) for ATV with high correlation coefficient >0.993.

**Precision**

Set of three different concentrations in three replicates of mixed standard solutions of RTV and ATV were prepared. All the solutions were analyzed on the same day in order to record any intra day variations in the results. Intra-day variation, as RSD (%), was found to be in the range of 0.22 to 0.63 for RTV and 0.41 to 1.05 for ATV. For Inter day variation study, three different concentrations of the mixed standard solutions in linearity range were analyzed on three consecutive days. Inter day variation, as RSD (%) was found to be in the range of 0.18 to 0.62 for RTV and 0.364 to 0.70 for ATV.

**Limit of detection (LOD) and Limit of quantitation (LOQ)**

LOD and LOQ were calculated as 3.3 \(\sigma/S\) and 10 \(\sigma/S\), respectively; where \(\sigma\) is the standard deviation of the response (y-intercept) and \(S\) is the slope of the calibration plot. The LOD of RTV and ATV were found 69.20 ng band\(^{-1}\) and 143.60 ng band\(^{-1}\), respectively. The LOQ of RTV and ATV were 209.72 ng band\(^{-1}\) and 434.56 ng band\(^{-1}\), respectively.

**Recovery Studies**

To check accuracy of the method, recovery studies were carried out by adding standard drug to sample at three different levels 50, 100 and 150 %. Basic concentration of sample chosen was 1000 ng band\(^{-1}\) of RTV and 3000 ng band\(^{-1}\) of ATV from tablet solution. The drug concentrations were calculated from respective linearity equation. The results obtained are shown in Table 2.

**Specificity**

The specificity of the method was ascertained by peak purity profiling studies. The peak purity values were found to be more than 991, indicating the no interference of any other peak of degradation product, impurity or matrix.

**Robustness Studies**

Robustness of the method was determined by carrying out the analysis under conditions during which mobile phase composition, mobile phase saturation, development distance, time from application to development and from development to scanning were altered and the effect on the area of drug were noted. The results are given in Table 3.

### Table 1: Data of forced degradation studies of ATV and RTV

<table>
<thead>
<tr>
<th>Stress conditions/ duration</th>
<th>ATV (%) Degradation</th>
<th>RTV (%) Degradation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acidic / 0.1 N HCl / Reflux half an hour</td>
<td>14</td>
<td>33</td>
</tr>
<tr>
<td>Alkaline /0.1 N NaOH/ Reflux for 2 hours</td>
<td>13</td>
<td>36</td>
</tr>
<tr>
<td>Oxidative /30 % H(_2)O(_2)/ Reflux for 3 hours</td>
<td>22</td>
<td>08</td>
</tr>
<tr>
<td>Neutral/H(_2)O/ Reflux for 1 hour</td>
<td>00</td>
<td>16</td>
</tr>
<tr>
<td>Photolysis UV/200 watt hours/square meter</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fluorescence /1,2 million lux hours</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dry heat/ 60(^\circ)C/ 7 days</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

### Table 2: Recovery Studies of ATV and RTV

<table>
<thead>
<tr>
<th>Drug</th>
<th>Amount taken (ng band(^{-1}))</th>
<th>Amount added (ng band(^{-1}))</th>
<th>Total amount found (ng band(^{-1}))</th>
<th>% Recovery</th>
<th>% RSD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTV</td>
<td>1000</td>
<td>500</td>
<td>1518.00</td>
<td>101.20</td>
<td>0.94</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>1000</td>
<td>2004.64</td>
<td>100.23</td>
<td>1.07</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>1500</td>
<td>2506.62</td>
<td>100.26</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>1500</td>
<td>4479.77</td>
<td>99.55</td>
<td>0.26</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>3000</td>
<td>6020.78</td>
<td>100.34</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>4500</td>
<td>7535.32</td>
<td>100.47</td>
<td>1.16</td>
</tr>
<tr>
<td>ATV</td>
<td>1000</td>
<td>500</td>
<td>1518.00</td>
<td>101.20</td>
<td>0.94</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>1000</td>
<td>2004.64</td>
<td>100.23</td>
<td>1.07</td>
</tr>
<tr>
<td></td>
<td>1000</td>
<td>1500</td>
<td>2506.62</td>
<td>100.26</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>1500</td>
<td>4479.77</td>
<td>99.55</td>
<td>0.26</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>3000</td>
<td>6020.78</td>
<td>100.34</td>
<td>0.45</td>
</tr>
<tr>
<td></td>
<td>3000</td>
<td>4500</td>
<td>7535.32</td>
<td>100.47</td>
<td>1.16</td>
</tr>
</tbody>
</table>

*Average of three determinations

### Table 3: Robustness Data in Terms of Peak Area (% RSD)

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Parameter</th>
<th>RTV % RSD</th>
<th>ATV % RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mobile phase composition (± 2 %)</td>
<td>0.08</td>
<td>0.02</td>
</tr>
<tr>
<td>2</td>
<td>Mobile phase saturation (± 10 %)</td>
<td>0.03</td>
<td>0.02</td>
</tr>
<tr>
<td>3</td>
<td>Time from application to development (0, 10, 20, and 30 min)</td>
<td>0.05</td>
<td>0.02</td>
</tr>
<tr>
<td>4</td>
<td>Development to scanning (0, 30, 60, and 90 min)</td>
<td>0.06</td>
<td>0.01</td>
</tr>
<tr>
<td>5</td>
<td>Development distance (± 10 %)</td>
<td>0.07</td>
<td>0.01</td>
</tr>
</tbody>
</table>

*Average of three determinations
Figure 1: Representative densitogram of mixed standard solution of RTV (2500 ng/band, $R_f = 0.25 \pm 0.004$) and ATV (5000 ng/band, $R_f = 0.41 \pm 0.004$)

Figure 2: Representative densitogram after acid treatment (a) ATV and (b) RTV with degradation product at $R_f$ 0.10, 0.14, 0.18, 0.32 and 0.36

Figure 3: Representative densitogram after alkali treatment (a) ATV and (b) RTV with degradation product at $R_f$ 0.32
CONCLUSION
The developed method is stability indicating and can be used for assessing the stability of RTV and ATV in bulk drug and pharmaceutical dosage form. The developed method is accurate, precise, specific and robust.

ACKNOWLEDGEMENT
The authors express their gratitude to Emcure Pharma Pvt. Ltd. (Pune, India) and Cipla Pvt. Ltd. (Kurkumbh, India) for the gift sample of pure RTV and ATV respectively.

REFERENCES
Deshpande Padmanabh B et al: HPTLC method for determination of Atazanavir and Ritonavir in tablet dosage forms


21. International Conference on Harmonization (ICH), Stability testing of new drug substances and products, Q1A (R2); 2003.

Source of support: Nil, Conflict of interest: None Declared

How to cite this article: